15-May-2024
Business Wire (Tue, 14-May 10:09 AM ET)
Merck discontinues testing of experimental skin cancer combo therapy
Seeking Alpha News (Mon, 13-May 7:58 AM ET)
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Business Wire (Thu, 9-May 4:05 PM ET)
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Business Wire (Thu, 9-May 4:05 PM ET)
GILD Bearish Calendar Put Spread is Inexpensive at 38 Cents
Market Chameleon (Thu, 9-May 3:36 PM ET)
GILD Bearish Calendar Put Spread Appears to be a Bargain at 36 Cents
Market Chameleon (Wed, 8-May 2:43 PM ET)
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Business Wire (Tue, 7-May 8:30 AM ET)
Gilead Sciences to Present at Upcoming Investor Conferences
Business Wire (Tue, 30-Apr 4:05 PM ET)
FDA Approves Biktarvy Label Update With Data for Pregnant Adults With HIV
Business Wire (Fri, 26-Apr 8:00 AM ET)
Gilead Sciences Announces First Quarter 2024 Financial Results
Business Wire (Thu, 25-Apr 4:02 PM ET)
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Gilead Sciences trades on the NASDAQ stock market under the symbol GILD.
As of May 15, 2024, GILD stock price declined to $67.01 with 4,825,977 million shares trading.
GILD has a beta of 0.45, meaning it tends to be less sensitive to market movements. GILD has a correlation of 0.07 to the broad based SPY ETF.
GILD has a market cap of $83.50 billion. This is considered a Large Cap stock.
Last quarter Gilead Sciences reported $7 billion in Revenue and -$1.32 earnings per share. This beat revenue expectation by $346 million and exceeded earnings estimates by $.17.
In the last 3 years, GILD stock traded as high as $89.74 and as low as $57.17.
The top ETF exchange traded funds that GILD belongs to (by Net Assets): VTI, VOO, QQQ, SPY, IVV.
GILD has underperformed the market in the last year with a price return of -10.4% while the SPY ETF gained +30.3%. GILD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.2% and +2.8%, respectively, while the SPY returned +6.6% and +5.5%, respectively.
GILD support price is $66.92 and resistance is $68.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GILD stock will trade within this expected range on the day.